MedTrace Logo

Intermediate-Sized Expanded Access Study

NCT05597436 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-09-02

No results posted yet for this study

Summary

This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.

Conditions

Interventions

DRUG

Trehalose

Once weekly 0.75g/kg administration

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Seelos Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Suma Babu, MD,MPH,MBBS · Massachusetts General Hospital

  • James D Berry, MD,MPH · Massachusetts General Hospital

  • Sabrina Paganoni, MD,PhD · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05597436 on ClinicalTrials.gov